{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:37:51Z","timestamp":1787999871029,"version":"build-2784847793"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.2169\/internalmedicine.9153-17","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T22:19:10Z","timestamp":1518128350000},"page":"1893-1897","source":"Crossref","is-referenced-by-count":31,"title":["Relapsed Myasthenia Gravis after Nivolumab Treatment"],"prefix":"10.2169","volume":"57","author":[{"given":"Ayumi","family":"Mitsune","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tojo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Ichinose","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.","DOI":"10.1056\/NEJMoa1507643"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015.","DOI":"10.1056\/NEJMoa1507643"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.","DOI":"10.1038\/nrc3239"},{"key":"4","unstructured":"4. Suzanne L, Topalian SL, Hodi FS, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 11-23, 2016."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2: 662-673, 2013.","DOI":"10.1002\/cam4.106"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol 17: 883-895, 2016.","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"7","unstructured":"7. Daido W, Yamasaki M, Saito N, et al. Effectiveness of nivolumab in large-cell neuroendocrine carcinoma of the lung - a report of two cases. Gan To Kagaku Ryoho (Cancer Chemother) 44: 59-62, 2017 (in Japanese, Abstract in English)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol 10: 1133-1141, 2015.","DOI":"10.1097\/JTO.0000000000000589"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rieber J, Schmitt J, Warth A, et al. Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. Eur J Med Res 20: 64, 2015.","DOI":"10.1186\/s40001-015-0158-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Varlotto JM, Medford-Davis LN, Recht A, et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol 6: 1050-1058, 2011.","DOI":"10.1097\/JTO.0b013e318217b6f8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK. Programmed death-1: from gene to protein in autoimmune human myasthenia gravis. J Neuroimmunol 193: 149-155, 2008.","DOI":"10.1016\/j.jneuroim.2007.09.019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26: 2375-2391, 2015.","DOI":"10.1093\/annonc\/mdv383"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 96: 259-260, 2016.","DOI":"10.2340\/00015555-2212"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2: 234-240, 2016.","DOI":"10.1001\/jamaoncol.2015.4368"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chana Weinstock, Harpreet Singh, Virginia Ellen Maher, Geoffrey Kim RP. FDA analysis of patients with baseline autoimmune diseases treated with PD-1\/PD-L1 immunotherapy agents [abstract]. J Clin Oncol 35 (Suppl): 3018, 2017.","DOI":"10.1200\/JCO.2017.35.15_suppl.3018"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28: 368-376, 2017.","DOI":"10.1093\/annonc\/mdw443"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2017 (Epub ahead of print).","DOI":"10.1001\/jamaoncol.2017.2925"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer 123: 1904-1911, 2017.","DOI":"10.1002\/cncr.30642"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107: 1055-1058, 2016.","DOI":"10.1111\/cas.12961"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46: 86-88, 2016.","DOI":"10.1093\/jjco\/hyv158"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun 6: 5997, 2015.","DOI":"10.1038\/ncomms6997"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Suzuki S. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66: 1334, 2009.","DOI":"10.1001\/archneurol.2009.229"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/13\/57_9153-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T23:31:42Z","timestamp":1603841502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/13\/57_9153-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9153-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}